Key result
Clozapine therapy links to reversible myocarditis presenting with subtle symptoms in a DiGeorge syndrome patient.
Why the study?
Clozapine-induced myocarditis is a rare but serious complication with limited pediatric cases documented, especially in patients with DiGeorge Syndrome.
Case Report (n=1)
This report highlights a rare case of clozapine-induced myocarditis in a pediatric patient with DiGeorge Syndrome, emphasizing the need for clinical vigilance for this potentially fatal complication.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to monitor for myocarditis in clozapine-treated DiGeorge adolescents; leaves open incidence and risk stratification.
DiGeorge Syndrome (22q11.2 deletion syndrome) is a chromosomal disorder associated with both congenital heart malformations and schizophrenia, which is often treatment-resistant and may warrant treatment with clozapine. Clozapine-induced myocarditis (CIM) is a rare complication of clozapine therapy, with a reported incidence ranging from 0.015% to 3%. Fulminant CIM has a nonspecific presentation in both adult and pediatric populations and a mortality rate approaching 50%. Few cases of pediatric CIM have been documented in the literature. This report highlights a case of CIM in an adolescent male with DiGeorge Syndrome whose clinical course was characterized by a subtle, nonspecific presentation and resolution with supportive care.
No takes yet. Share an insight, caveat, or question.
Ruhe et al. (2018) conducted a case report in Clozapine-induced myocarditis and DiGeorge Syndrome (n=1). Clozapine was evaluated on Clinical course of clozapine-induced myocarditis. Clozapine therapy in an adolescent male with DiGeorge Syndrome resulted in clozapine-induced myocarditis, which presented with subtle, nonspecific symptoms and resolved with supportive care.
Synapse has enriched 10 related papers. Consider them for comparative context: